Inhaltsverzeichnis
News
27.09.2019 September 2019: Impact of post-mastectomy radiotherapy (RT) after neoadjuvant chemotherapy (NACT) on survival in breast cancer patients
Results of a retrospective pooled analysis from three randomized neoadjuvant GBG trials (GeparTrio, GeparQuattro and GeparQuinto) evaluating the impact of post-mastectomy RT (PMRT) after NACT on survival in breast cancer patients have been published in the Annals of Surgical Oncology.
Mehr ...17.09.2019 GBG Research at ESMO 2019
Data of several GBG research projects will be presented at the upcoming ESMO 2019, which will take place from September 27 to October 1, 2019 in Barcelona, Spain.
Mehr ...12.09.2019 August 2019: Results of a pooled analysis from two randomized phase III trials [LEA GBG51 and Cancer and Leukemia Group (CALGB) 40503] evaluating the addition of bevacizumab to endocrine therapy (ET) as first-line treatment for hormone receptor (HR)-positive metastatic breast cancer (MBC)
Data from two similar randomized phase III trials (LEA GBG51 and CALGB 40503) comparing the efficacy of standard ET versus experimental ET plus bevacizumab as first-line treatment for HR-positive MBC have been published in the European Journal of Cancer
Mehr ...10.09.2019 Save the date: AGO State of the Art Meeting 2020
The AGO State of the Art Meeting 2020 will take place 29th of February at the InterContinental Hotel, Wilhelm-Leuschner-Straße 43, 60329 Frankfurt. Please save the date!
Mehr ...10.09.2019 Save the date: GBG Annual Meeting 2020
The GBG Annual Meeting 2020 will take place 27.-28. February at the InterContinental Hotel, Wilhelm-Leuschner-Straße 43, 60329 Frankfurt.. Please save the date!
Mehr ...
GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440